Evidence map›Paper›PMID 26392415›Full record

Trial reportOncotarget2015

Concurrent radiotherapy with gefitinib in elderly patients with esophageal squamous cell carcinoma: Preliminary results of a phase II study.

Yaping Xu, Yuanda Zheng, Xiaojiang Sun, Xinmin Yu, Jialei Gu, Wei Wu, Gu Zhang, Jinlin Hu, Wenyong Sun, Weimin Mao

Open access · diamondAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. The outcomes of radiotherapy and factors that predict overall survival in elderly patients with esophageal squamous cell carcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2017
    Article
  16. Current Status and Future Prospects for Esophageal Cancer Treatment.Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia · 2017
    Review
  17. Review
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Yaping XuSchool of Medicine, Shandong University, Jinan, China.
Yuanda ZhengDepartment of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
Xiaojiang SunDepartment of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
Xinmin YuDepartment of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
Jialei GuDepartment of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
Wei WuDepartment of Pathology, Zhejiang Cancer Hospital, Hangzhou, China.
Gu ZhangDepartment of Pathology, Zhejiang Cancer Hospital, Hangzhou, China.
Jinlin HuDepartment of Pathology, Zhejiang Cancer Hospital, Hangzhou, China.
Wenyong SunDepartment of Pathology, Zhejiang Cancer Hospital, Hangzhou, China.
Weimin MaoZhejiang Key Laboratory of The Diagnosis & Treatment Technology on Thoracic Oncology, Hangzhou, China.
Zhejiang Cancer Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The survival rate associated with esophageal cancer is very poor due to diagnosis at advanced stages of disease and insensitivity to chemotherapy. This study investigated the efficacy of gefitinib combination with radiation in 20 elderly patients with esophageal squamous cell carcinoma (ESCC) who were not eligible for platinum-based chemotherapy. Immunohistochemistry was performed to analyze epidermal growth factor receptor (EGFR) expression, and the amplified refractory mutation system was used to detect EGFR mutations. Treatment response was assessed by endoscopy and computed tomography. Treatment toxicity was evaluated using the National Cancer Institute's Common Toxicity Criteria. The data showed that among these 20 patients, 5 experienced a complete response (CR), 13 a partial response (PR), and 2 had stable disease. The overall response rate (CR + PR) was 90%, the median overall survival (OS) was 14.0 months (95% confidence interval [CI]: 10.0-17.9 months), and the median progression-free survival was 7.0 months (95% CI: 0-17.2 months). Patients with good Eastern Cooperative Oncology Group performance status, never smoking, and EGFR mutated tumors had the best OS (14.0, 14.0, and 17.0 months, respectively). Treatment-related grade 3/4 toxicity occurred in five patients. No case of grade 3/4 impaired liver function or hematological toxicity was observed. Concurrent radiotherapy with gefitinib is effective and tolerable in elderly ESCC patients.

Indexed as

AgedAged, 80 and overAge FactorsAntineoplastic AgentsCarcinoma, Squamous CellChemoradiotherapyChinaDisease-Free SurvivalDisease ProgressionDNA Mutational AnalysisErbB ReceptorsEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaEsophagoscopyFemaleGefitinibAntineoplastic AgentsEGFR protein, humanErbB ReceptorsGefitinibProtein Kinase InhibitorsQuinazolineselderly patientsepidermal growth factor receptoresophageal cancergefitinibradiotherapy

Identifiers

PMID26392415
PMCPMC4742011
OpenAlexW2165311092

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.